PPARG c.1347C > T polymorphism is associated with cancer susceptibility: From a case-control study to a meta-analysis

Abstract

Recently, several studies suggested that PPARG c.1347C > T polymorphism was correlated with cancer risk. However, past results remained controversial. In this study, we performed a case-control study on the relationship of PPARG c.1347C > T polymorphism with risk of non-small cell lung cancer (NSCLC) and subsequently carried out a meta-analysis to further assess the association between PPARG c.1347C > T and overall cancer. In our case-control study, after adjusting by age, sex, body mass index (BMI), smoking and drinking, a tendency to increased NSCLC risk was noted (CT/TT vs. CC: adjusted OR, 1.21; 95% CI, 0.97-1.51; P = 0.097). In the meta-analysis, we found a significant association between PPARG c.1347C > T polymorphism and overall cancer risk (T vs. C: OR, 1.13; 95% CI, 1.03-1.23; P = 0.006; TT vs. CC: OR, 1.29; 95% CI, 1.07-1.56; P = 0.008, CT/TT vs. CC: OR, 1.11; 95% CI, 1.02-1.21; P = 0.014 and TT vs. CT/CC: OR, 1.26; 95% CI, 1.04-1.52; P = 0.016). In a subgroup analysis by ethnicity, evidence of significant association between PPARG c.1347C > T polymorphism and cancer risk was found among Asians and mixed populations. In a subgroup analysis by cancer type, PPARG c.1347C > T polymorphism was associated with risk of esophageal cancer and glioblastoma. In addition, in a subgroup analysis by origin of cancer cell, evidence of significant association between PPARG c.1347C > T polymorphism and cancer risk was also found among epithelial tumor. In conclusion, the findings indicate PPARG c.1347C > T polymorphism may increase the susceptibility of cancer.